Research programme: pancreatic stem cell therapy - Microbot Medical

Drug Profile

Research programme: pancreatic stem cell therapy - Microbot Medical

Latest Information Update: 13 Dec 2016

Price : $50

At a glance

  • Originator StemCells
  • Class Stem cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 28 Nov 2016 StemCells has been acquired by Microbot Medical
  • 19 Jul 2012 Development discontinued for Type-1 diabetes mellitus in USA before July 2012
  • 08 May 2008 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top